Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00048854 |
This study will determine whether characteristics of women with Premenstrual Syndrome influence response to treatment with serotonin reuptake inhibitors and whether SRIs can alleviate premenstrual symptoms.
Condition | Intervention | Phase |
---|---|---|
Premenstrual Syndrome |
Drug: Sertraline Other: Treatment as usual (TAU) |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder |
Estimated Enrollment: | 120 |
Study Start Date: | September 2001 |
Estimated Study Completion Date: | October 2008 |
Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Participants will receive treatment as usual
|
Other: Treatment as usual (TAU)
At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
|
2: Experimental
Participants will take sertraline
|
Drug: Sertraline
Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
|
Moderate to severe premenstrual disturbances afflict up to 20 percent of women. Studies have shown the use of serotonin reuptake inhibitors (SRIs) during the luteal phase of the menstrual cycle to be effective in improving symptoms in women with premenstrual dysphoric disorder (PMDD). Unfortunately, SRI treatment has only been evaluated in controlled clinical trials, and evidence suggests that patients in these clinical trials are not representative of women commonly seen in clinical practice. Thus, the real-world feasibility of intermittent dosing is questionable.
Patients in this study receive sertraline (Zoloft) during the luteal phase of their menstrual cycle every month for 6 months. The dose may be modified based on structured interviews with the patients. Assessments include questionnaires and interviews which take place at study start, at midpoint, and at the end of the study.
Ages Eligible for Study: | 18 Years to 48 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Yale University School of Medicine ( Kimberly Yonkers, MD ) |
Study ID Numbers: | R21 MH62379, DSIR AT-SO |
Study First Received: | November 8, 2002 |
Last Updated: | August 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00048854 History of Changes |
Health Authority: | United States: Federal Government |
Neurotransmitter Agents Depression Menstruation Disturbances Mental Disorders Psychotropic Drugs Mood Disorders |
Sertraline Depressive Disorder Serotonin Uptake Inhibitors Serotonin Antidepressive Agents Premenstrual Syndrome |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Depressive Disorder Serotonin Uptake Inhibitors Pharmacologic Actions Serotonin Agents |
Pathologic Processes Menstruation Disturbances Mental Disorders Syndrome Therapeutic Uses Mood Disorders Sertraline Central Nervous System Agents Premenstrual Syndrome Antidepressive Agents |